Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01992549 · ClinicalTrials.gov registry record · Phase 3
Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII
A Phase 3 study of Severe Hemophilia A, sponsored by Octapharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 48
- Enrollment target
- 15
- Study locations
NCT01992549 is a Phase 3 study of Severe Hemophilia A that has completed, run by Octapharma. The registered enrollment target is 48 participants, below the 59-participant average among 4 other Severe Hemophilia A trials with a reported enrollment target (19% lower). The trial reports 15 study locations across 5 states.
The verdict
NCT01992549, a Phase 3 study of Severe Hemophilia A, has completed, sponsored by Octapharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 48 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of the study is to collect long-term data on the inhibitor development rate of Human-cl rhFVIII in previously untreated patients with severe Hemophilia A.
Conditions Studied
Interventions
- BIOLOGICAL Human-cl rhFVIII
Study Locations (15)
Other
- Hospital for Sick Children - Toronto
- Hopital de la Timone - Marseille
- Hôpital Kremlin Bicètre - Paris
- Institute of Hematology and Transfusiology - Tbilisi
- Sahyadri Speciality Hospital - Pune
- Christian Medical College - Vellore
- IMSP Mother and Child Institute - Chisinau
- University Medical School - Warsaw
- The National Children Specialized Hospital "OHMATDET" - Kiev
- Danylo Halytsky Lviv National Medical University - Lviv
- Great Ormond Street Hospital for Children - London
California
- UC Davis Medical Center - Sacramento
Alberta
- University of Alberta - Edmonton
British Columbia
- BC Children's Hospital - Vancouver
Ontario
- McMaster Children's Hospital - Hamilton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2014-04 |
| Est. Completion | 2018-12-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01992549
The ClinicalTrials.gov registry entry for NCT01992549 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 59-participant average among 4 other Severe Hemophilia A trials with a reported enrollment target (19% lower). The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Severe Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which Human-cl rhFVIII is the first listed.
NCT01992549 reports 15 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Alberta.
Frequently Asked Questions
What is clinical trial NCT01992549 about?
NCT01992549 is a clinical study titled "Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII". The purpose of the study is to collect long-term data on the inhibitor development rate of Human-cl rhFVIII in previously untreated patients with severe Hemophilia A.
What is the current status of trial NCT01992549?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 48 participants. The study started on 2014-04. Estimated completion is 2018-12-27.
What conditions does trial NCT01992549 study?
This clinical trial studies the following conditions: Severe Hemophilia A.
What interventions are being tested in trial NCT01992549?
The interventions under investigation include: Human-cl rhFVIII (BIOLOGICAL).
Who is sponsoring clinical trial NCT01992549?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01992549 being conducted?
This trial has 15 study locations across California, Alberta, British Columbia, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
RECRUITING · Phase 1
-
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
RECRUITING · Phase 4
-
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.